Oruka Therapeutics (NASDAQ:ORKA) Shares Gap Down – What’s Next?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) gapped down before the market opened on Thursday . The stock had previously closed at $93.29, but opened at $90.84. Oruka Therapeutics shares last traded at $85.7160, with a volume of 632,865 shares traded.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. UBS Group boosted their price objective on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday. Guggenheim set a $200.00 target price on shares of Oruka Therapeutics and gave the stock a “buy” rating in a report on Monday, April 27th. Leerink Partners set a $120.00 price target on shares of Oruka Therapeutics in a report on Thursday, April 30th. Stifel Nicolaus upped their price target on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a report on Friday, March 13th. Finally, Weiss Ratings downgraded shares of Oruka Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $134.30.

Oruka Therapeutics Stock Performance

The stock has a 50-day moving average of $68.47 and a 200-day moving average of $48.77. The firm has a market cap of $5.07 billion, a price-to-earnings ratio of -43.43 and a beta of -0.36.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.04. Sell-side analysts predict that Oruka Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.

Insider Buying and Selling at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,947 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $69.28, for a total transaction of $550,568.16. Following the completion of the transaction, the insider owned 32,718 shares in the company, valued at approximately $2,266,703.04. This represents a 19.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $69.69, for a total transaction of $120,494.01. Following the transaction, the chief executive officer owned 925,580 shares of the company’s stock, valued at approximately $64,503,670.20. This represents a 0.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 185,407 shares of company stock worth $11,636,307. Company insiders own 23.49% of the company’s stock.

Institutional Trading of Oruka Therapeutics

Large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada grew its position in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after acquiring an additional 365 shares during the period. Los Angeles Capital Management LLC acquired a new stake in Oruka Therapeutics in the 4th quarter valued at about $37,000. PNC Financial Services Group Inc. acquired a new stake in Oruka Therapeutics in the 3rd quarter valued at about $39,000. Caitong International Asset Management Co. Ltd bought a new position in Oruka Therapeutics during the fourth quarter worth about $67,000. Finally, Russell Investments Group Ltd. bought a new position in Oruka Therapeutics during the third quarter worth about $43,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.